A61K 2239/15
Non-antibody based
A61K2239/15 (Non-antibody based) appears on 21 US grants and 136 published applications in this corpus.
Search patents in A61K- Granted patents
- 21
- Published applications
- 136
- Assignees
- 94
- Inventors
- 373
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 4 |
| 2018 | 1 | 1 |
| 2019 | 1 | 5 |
| 2020 | 3 | 1 |
| 2021 | 0 | 2 |
| 2022 | 3 | 3 |
| 2023 | 2 | 10 |
| 2024 | 2 | 55 |
| 2025 | 3 | 32 |
| 2026 | 3 | 17 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Synthetic pathway activators14 Jul 2026US 12,679,881 B2Arsenal Biosciences, Inc.
- Chimeric Tim receptors and uses thereof9 Jun 2026US 12,648,964 B2Cero Therapeutics Holdings, Inc.
- Compositions and methods of NKG2D chimeric antigen receptor T cells for controlling triple-negative breast cancer12 May 2026US 12,624,085 B2The Trustees of the University of Pennsylvania
- Chimeric antigen receptor constructs and their use in CAR-T cells25 Nov 2025US 12,479,890 B2The University of North Carolina at Chapel Hill
- Targeting the PVR axis using CAR T cell therapy and combinations28 Oct 2025US 12,453,772 B2Roswell Park Cancer Institute
- A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:011 Oct 2026US 2026/0297157 A1Board of Regents, The University of Texas System
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
- Immune cells with chimeric antigen receptors or chimeric autoantibody receptors27 Aug 2026US 2026/0248850 A1Saliogen Therapeutics, Inc.
- Synthetic pathway activators27 Aug 2026US 2026/0250355 A1Arsenal Biosciences, Inc.
- Chimeric cd8-alpha co-receptor compositions and methods of use20 Aug 2026US 2026/0242442 A1Poseida Therapeutics, Inc.
Most cited
By later US patents
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013
- Use of chimeric antigen receptor modified cells to treat cancer13US 9,932,405 B2Innovative Cellular Therapeutics, Inc. · 2018
- Chimeric immunoreceptor useful in treating human cancers5US 9,217,025 B2City of Hope · 2015
- Compositions and methods of chimeric autoantibody receptor T cells4US 10,301,370 B2The Trustees of the University of Pennsylvania · 2019